Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

By December 2023, 12.3% of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutideStudy will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2 ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to ...

The Dallas Mavericks will end their four-game road trip against the Chicago Bulls on Saturday. Dallas won its last game against the Orlando Magic on Thursday and will look to make it two in a row ...